Table 4.
Comparison of Studies Examining Long-Term Outcomes after HD-ASCT for Relapsed/Refractory HL
| Author | Date | Study Duration | N | % ABVD |
R/P | Median f/u time (yrs) |
% EFS | %OS | Comment |
|---|---|---|---|---|---|---|---|---|---|
| Bierman | 2002 | 1984–1999 | 379 | NS^ | R | 5.1 | 24 (10y) | 32 (10y) | |
| Stiff | 2003 | 1990–1995 | 74 | 14 | P | 10 | 41 (5y) | 54 (5y) | No late events in sensitive* pts; some late events in resistant† pts |
| Moskowitz | 2004 | 1985–1998 | 75 | 81.3 | P | 10 | 45 (10y) | 48 (10y) | OS, EFS plateau |
| Lavoie | 2005 | 1985–1992 | 100 | NS^ | P | 11.4 | 51(15y) | 54 (15y) | OS plateau |
| Majhail | 2006 | 1985–2003 | 141 | 63.8 | R | 6.3 | 48 (5y) | 53 (5y) | OS plateau, some late events |
| Sirohi | 2008 | 1985–2005 | 195 | NS^ | P | 10.3 | 44 (5y) | 55 (5y) | |
| Smith | 2011 | 1995–2008 | 214 | 82.7 | R | 6 | 45 | 55 | Study limited to early relapses; EFS plateau |
| URMC | 2011 | 1990–2006 | 95 | 100 | R | 8.2 | 37 (5y) | 54 (5y) | Notable late events |
NS, not specified; R, retrospective study; P, prospective study; sensitive*, chemosensitive disease; resistant,†, chemoresistant disease